Emerging research from Workit Labs

Workit Labs is a team of experts committed to advancing the understanding of substance use disorder treatment through scientific research and analysis. The Workit Labs team generates insights that inform our innovative strategies, and share our discoveries with the wider healthcare community.

Supportive perinatal care

Excellent maternal SUD outcomes

79%

Received continuous OUD care

Of these, 8.0% transferred care to prenatal clinicians and 71.8% continued to receive telemedicine OUD care from Workit Health.

94%

Retention throughout pregnancy

Of those who remained with Workit Health instead of transferring care to a prenatal clinic, 94.2% continued care through 6-weeks post-pregnancy.

100%

Adherence

100% of participants tested positive for buprenorphine in post-pregnancy urine drug screens, demonstrating excellent adherence to the treatment program.

Reaching rural areas

Metrics that matter

62%

3-month retention

Compare this to 50% 3-month retention rates reported in extant studies on telemedicine-delivered OUD treatment among patients living in both rural and rural/non-rural areas.

99%

Adherence

Urinary drug screens showed 99% of participants tested positive for buprenorphine at all time points, demonstrating strong adherence to the treatment program and very little diversion.

79%

Tested negative for other substances

Workit Health's focus on harm reduction encouraged participation and allowed participants to remain active and engaged without fear of dismissal, despite ~20% of participants testing positive for unexpected substances in their urinary drug screens. 

Areas of research focus

Our current areas of study include:

Our publications and presentations

Telehealth Treatment for Opioid Use Disorder During Pregnancy

March 14, 2023

by M. Justin Coffey, MD; Maxwell Weng, BSE; Cynthia Jimes, PhD; Shannon Brigham, PA-C; Marlene C. Lira, MPH. Published in JAMA Network Open

Rising Patient Volume and Acuity Challenge Mental and Behavioral Health Care Access

December 20, 2023

by M. Justin Coffey, M.D. Published in NEJM Catalyst Innovations in Care Delivery

Retention in Telehealth Treatment for Opioid Use Disorder among Pregnant People

June 20, 2023

Presented at the 2023 College on Problems of Drug Dependence Meeting

Innovations in Small Business Telehealth Technologies for Substance Use Disorders: Automated Assessments, Electronic Health Record Integrations, and Medication Shipping

June 19, 2023

Poster presented at the 2023 College on Problems of Drug Dependence Meeting.

Chatbots: Increasing Patient and Provider Engagement in Substance Use Disorder Care

May 21, 2023

Presented at the 2023 American Psychiatric Association Meeting

Retention in Telehealth Treatment for Opioid Use Disorder Among Rural Populations: A Retrospective Cohort Study

May 15, 2023

Published in Telemedicine and e-Health

Retention in Telehealth Treatment for Opioid Use Disorder Among Rural Populations

April 14, 2023

Poster presented at the American Society of Addiction Medicine 54th Annual Conference

Workit Labs is committed to exploring innovations in addiction medicine and telehealth technologies through dedicated research and academic rigor

This site uses cookies to improve your experience. By using this site, you consent to our use of cookies.